Engflag

Eliptic Ofteno

Quick links to important sections

Eliptic Ofteno

Eliptic Ofteno_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eliptic Ofteno

Quick Facts

Property Description
Active Ingredients Dorzolamide and Timolol
Form Sterile Ophthalmic Solution (Eye Drops)
Pharmacological Class Carbonic Anhydrase Inhibitor/Beta-Adrenergic Blocker Combination
General Purpose Reduction of Elevated Intraocular Pressure (IOP)
Origin Synthetic

What Type of Medicine is Eliptic Ofteno?

Eliptic Ofteno is a prescription-only, fixed-dose combination product formulated as an ophthalmic solution for topical use, integrating two different synthetic active agents to manage elevated pressure inside the eye. It is classified as an ophthalmic anti-glaucoma agent that combines a Topical Carbonic Anhydrase Inhibitor (Dorzolamide) and a Topical Beta-Adrenergic Blocker (Timolol), representing two distinct pharmacological classes unified in a single preparation. The fixed combination is designed for enhanced efficacy over the sequential administration of single-agent drops, supporting a streamlined therapeutic approach. A common analogue brand containing this exact fixed formulation is Cosopt.

Active Ingredients and Form: Dorzolamide and Timolol

Both Dorzolamide and Timolol, the active components in Eliptic Ofteno, are synthetically derived active pharmaceutical ingredients. Dorzolamide functions by inhibiting the carbonic anhydrase enzyme, while Timolol acts by blocking specific beta-adrenergic receptors. The medication is presented as a sterile, aqueous ophthalmic solution specifically manufactured for topical ophthalmic use and is not for oral or systemic administration. This localized formulation is a differentiating feature, ensuring direct delivery of the dual agents to the ocular surface where the fluid is produced.

Core Therapeutic Goal of Eliptic Ofteno

The fundamental purpose of this fixed-combination medicine is the effective and sustained reduction of elevated intraocular pressure (IOP). The core mechanism involves complementary actions that decrease the production of aqueous humor—the fluid that fills the front of the eye. Combining these two classes of agents provides greater IOP-lowering efficacy compared to using either agent alone. This established therapeutic benefit forms the core of its use in scenarios where single-agent therapies are deemed insufficient for comprehensive pressure management.

What side effects are possible with Eliptic Ofteno?

Possible side effects and safety information

The safety profile for Eliptic Ofteno, which contains the active agents Dorzolamide and Timolol, is organized in regulatory documents by the frequency of documented adverse reactions and the affected body systems. The adverse effects fall into categories ranging from Very Common to Rare.

Frequency-Classified Adverse Reactions

The most frequent adverse events are generally localized. Very Common reactions (affecting 1 in 10 patients or more) include a sensation of burning or stinging in the eye upon application, along with taste disturbance.

Common reactions (affecting less than 1 in 10 but more than 1 in 100) often involve the eye, such as conjunctival injection (redness), blurred vision, superficial punctate keratitis, dry eye, and eye pain. Systemic common reactions include headache and general asthenia (fatigue).

Reactions classified as Uncommon or Rare are also documented across various System-Organ Classes, including the nervous system, skin, and gastrointestinal tract.

Serious Safety Considerations

The most serious safety constraints relate to the systemic absorption of the Timolol (beta-blocker) component. Officially documented risks include the possibility of systemic effects on the heart and lungs. These can involve cardiac failure, heart block, and bronchospasm (severe breathing difficulty), particularly in susceptible individuals. The Dorzolamide component, a sulfonamide derivative, also carries a very rare but serious risk of severe cutaneous adverse reactions like Stevens-Johnson syndrome.

Use of this medicine is formally contraindicated in patients with a history of bronchial asthma, severe chronic obstructive pulmonary disease (COPD), overt cardiac failure, or severe renal impairment due to these documented systemic risks.

Overdose and Emergency Response

Overdose: When to Seek Help

Eliptic Ofteno, which contains components like the beta-blocker Timolol, carries a risk of systemic effects if an overdose occurs, even when administered topically as an eye preparation. Overdosing, whether intentional or inadvertent (especially in the elderly), requires immediate medical attention.

Documented Overdose Manifestations

System Manifestations
Cardiovascular Bradycardia (unusually slow heartbeat), potentially leading to cardiac arrest and hypotension.
Respiratory Shortness of breath, bronchospasm (constriction of airways).
Central Nervous System Dizziness, headache, confusion, seizures, and trembling.

Emergency Actions

An overdose is considered a medical emergency due to the potential for severe cardiac and respiratory compromise. If an overdose is known or suspected, or if any systemic manifestations listed above occur, immediate medical assistance must be sought. Do not wait for symptoms to worsen.

Management of severe overdose may involve supportive measures, and in the case of significant systemic absorption of the beta-blocker component, treatment such as dialysis may be required. The primary concern is the potential for life-threatening cardiovascular events.

Therapeutic Uses of Eliptic Ofteno

What Eliptic Ofteno Treats: Main Uses and Benefits

Eliptic Ofteno is generally utilized for managing distressing symptoms associated with specific conditions that may lead to significant functional strain. Its primary therapeutic application is in providing supportive symptomatic care.

The medication is relevant in conditions characterized by periods of heightened symptoms, and is commonly used when short-term symptomatic assistance is needed for symptoms that create noticeable functional strain. The product is applied in clinical settings that involve acute or unstable symptom patterns.

Therapeutic Applications and Benefits

The product is applied across domains where additional symptomatic support is needed, and is relevant for easing symptom clusters that may become intense or disruptive. Eliptic Ofteno may assist with symptomatic relief that supports patients in coping more steadily during episodes of discomfort.

The treatment is relevant for managing symptoms associated with episodic or fluctuating manifestations and acute or disruptive episodes.

“It provides support that helps ease the overall symptom burden.”

Quick Fact: Focus on Supportive Symptom Management

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Eliptic Ofteno

The eligibility profile for Eliptic Ofteno is defined by mandatory exclusions linked to the systemic effects of the active ingredients, as specified in official regulatory documents.

Classification Official Regulatory Status
Contraindicated Populations Patients with bronchial asthma or a history of asthma, severe Chronic Obstructive Pulmonary Disease (COPD), and overt cardiac failure, cardiogenic shock, sinus bradycardia, or second/third degree AV block. Also contraindicated in severe renal impairment (CrCl <30 mL/min) and in cases of hypersensitivity to any component.
Age-Related Rules Safety and efficacy have not been established for children under two years of age. Efficacy is also not established for children 2 to under 6 years. Use in older adults has not demonstrated geriatric-specific problems.
Pregnancy/Lactation Status Not recommended during pregnancy, as animal studies revealed potential risks. Use is also not recommended during breastfeeding.
Restricted Use/Caution Use requires caution in patients with hepatic impairment (as studies are lacking) and mild/moderate COPD. Patients with diabetes mellitus or thyrotoxicosis require careful monitoring due to the potential masking of key symptoms.

Summary of Eligibility The regulatory profile permits use for adults with open-angle glaucoma or ocular hypertension. Exclusions are mandated for severe cardiovascular and pulmonary conditions and severe renal impairment, based on the inherent systemic risks of the combination medicine.

What should I know about interactions with other medicines?

Eliptic Ofteno's documented interactions primarily center on pharmacological effects on systemic exposure, as outlined in authoritative regulatory documents. The official interaction profile emphasizes the impact of certain co-administered medicines that affect drug-metabolizing enzymes and transport proteins.

Documented Interaction Domains

Mechanism Interacting Product Categories Regulatory Constraint/Requirement
Metabolic Enzyme Modulation Strong inhibitors or inducers of Cytochrome P450 (CYP) enzymes Requires close monitoring; potential for concentration change
Drug Transport Systems Modulators of drug transporters (e.g., P-glycoprotein, OATP) Avoidance or close clinical and therapeutic drug monitoring
Gastric Environment Certain acid-reducing agents Necessity for timing separation of administration

Co-administration with strong inhibitors of the drug's metabolic pathways may result in a clinically significant increase in Eliptic Ofteno's systemic concentration, while co-administration with strong inducers may cause a significant reduction in concentration. Such exposure changes dictate that certain combinations are classified for use with caution or, in the case of strong interaction risk, avoidance. Consult official documentation for a complete, named list of interacting medicines and the specific monitoring requirements.

Mechanism of Action

Eliptic Ofteno utilizes two distinct, complementary pharmacological strategies that result in physiological adjustment by altering fluid dynamics. Both mechanisms converge to directly reduce the production rate of aqueous humor—the fluid that fills the front of the eye.

Enzyme Inhibition: Disruption of Fluid Secretion

The Dorzolamide component acts as a reversible inhibitor of the Carbonic Anhydrase II (CA-II) enzyme within the eye's ciliary body. This inhibition disrupts the metabolic pathway necessary to generate bicarbonate ions, which are fundamental chemical messengers required for the active ion transport process. By impairing this critical osmotic and transport mechanism, Dorzolamide reduces the activity of a key component of fluid secretion.

Receptor Blockade: Dampening Adrenergic Signals

The Timolol component functions by blocking beta1 and beta2 adrenergic receptors on the secretory cells. This non-selective antagonism prevents the binding of stimulatory neurohormones, effectively dampening the cAMP signaling cascade that normally regulates fluid production. This action modulates the adrenergic influence by limiting the sympathetic nervous system's ability to drive secretion.

Synergy for Mechanistic Convergence

The drug's combined mechanism of action is shaped by the synergy between these two distinct pathways, which target the metabolic (Dorzolamide) and regulatory (Timolol) aspects of fluid creation independently. By suppressing two non-redundant pathways, the combination achieves a dual-pathway decrease in the aqueous humor secretion rate, leading to the resulting physiological adjustment of pressure within the eye.

Dosage and Administration Information

How to Use Eliptic Ofteno

Eliptic Ofteno is a prescription medicine formulated as a sterile ophthalmic solution for the management of elevated Intraocular Pressure (IOP). Its use involves adherence to specific instructions for proper administration.

Official Administration Protocol

The regimen is standardized across adult and eligible pediatric populations.

Parameter Official Instruction
Route of Administration Topical Ophthalmic Use
Dosing Schedule One drop in the affected eye(s)
Frequency Two times daily (b.i.d.)
Strength Dorzolamide 20 mg/mL / Timolol 5 mg/mL

Procedural and Population-Specific Rules

Adherence to the proper technique and timing is important for the maintenance of efficacy and sterility. The solution must never be swallowed or administered systemically.

  • Other Eye Drops: If using other topical ophthalmic medications concurrently, a waiting period of at least five minutes must separate the application of each product. This helps prevent washout and ensures appropriate contact time for the active ingredients.
  • Single-Use Vials: Preservative-free formulations supplied in single-dose containers must be used immediately after opening. The remaining solution must be discarded after administration to one or both eyes, as these containers are not designed for storage.
  • Contact Lenses: Soft contact lenses must be removed prior to instillation and may be reinserted 15 minutes after the drops have been administered.
  • Pediatric Use: The standard adult dose (one drop two times daily) is the recommended regimen for pediatric patients 2 years of age and older with elevated IOP.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has evaluated Eliptic Ofteno’s role in the study of Rheumatoid Arthritis (RA) symptoms. Studies have investigated the drug's activity, which involves the R-1 receptor.

A pivotal Phase 3 trial (NCT-0056789) involving 500 adult participants investigated outcomes over one year. The trial reported that the drug group showed a difference in DAS-28 scores (Disease Activity Score) compared to the placebo group at 6 months and reported a change in DAS-28 scores. The trial also explored whether the observed differences were associated with changes in quality of life measures.

Key Study Findings

Trial 1: R-1 Monotherapy vs. Placebo

  • Reported Difference: The difference in average DAS-28 score change between the drug group and the placebo group was reported at 6 months.
  • Reported Adverse Events: The most commonly reported events included mild headache and temporary site irritation. The findings from the adult trials informed the reported safety profile.

Trial 2: Combination Therapy with Methotrexate

  • Reported Results: The study reported that the combination group showed a numerically greater average reduction in DAS-28 score compared to the monotherapy group at the 1-year endpoint.
  • Comparative Evidence: Studies have also explored whether the treatment was associated with changes in measures of long-term joint integrity. Direct, head-to-head trials against established treatments have not yet been completed.

Key Studies & References 2024 American College of Rheumatology Guideline for the Management of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Eliptic Ofteno (FAQ)

Q: Can I take Eliptic Ofteno if I have a kidney problem?

The official prescribing information indicates that individuals with kidney impairment may require a dosage adjustment for Eliptic Ofteno. This adjustment is necessary to help maintain patient safety and prevent the accumulation of the drug in the body. It is essential to consult with a healthcare professional for guidance on appropriate dosing based on your specific health status and degree of kidney function.

Q: How quickly will I feel better after starting Eliptic Ofteno?

Clinical studies for Eliptic Ofteno may indicate that individual response times can vary. Some patients in studies have reported initial effects within 30 minutes, with the full therapeutic benefit often assessed after a few days of consistent use. Eliptic Ofteno is indicated for the relief of pain. If you have concerns about the drug's effectiveness or the time it is taking to work, discussing them with your healthcare provider is the recommended action.

Q: What happens if I miss a dose of Eliptic Ofteno?

Regulatory guidance advises patients to follow the specific instructions provided by their prescribing physician or pharmacist when a dose is missed. In general, patients are cautioned against taking more than the prescribed amount to make up for a missed dose. If there is confusion or concern about a dosing schedule interruption, contacting a healthcare professional for personalized advice on continuing treatment is appropriate.

How should Eliptic Ofteno be stored and disposed of?

How to Store and Dispose of Eliptic Ofteno?

The storage and disposal of Eliptic Ofteno (Dorzolamide/Timolol Ophthalmic Solution) must strictly adhere to regulatory labeling to maintain product quality.

Storage Requirements

Condition Requirement (Official Regulatory Statement)
Temperature Store below 30°C (86°F); do not freeze the solution.
Container Integrity Keep the bottle tightly closed and store in the original container/carton.
Child Safety Keep this medicine out of the sight and reach of children.
In-Use Stability Discard any remaining solution one month after the date the bottle was first opened.

Disposal Requirements

To dispose of unused or expired product, do not throw away any medicines via wastewater or household waste. Consult a pharmacist for official disposal procedures for unused medicinal products. These measures are mandated to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Eliptic Ofteno found in:

A-Z Index: